USP and Public Policy
Left
Refine Your Search
USP comments to FDA on “Periodic Review of Existing Regulations: Retrospective Review Under E.O. 13563.” Docket No. FDA–2011–N–0259. Comments were submitted in 2019.
Learn More
USP comments to FDA on "FDA Food Safety Modernization Act: Title III--A New Paradigm for Importers. Docket Nos. FDA-2011-N-0134, FDA-2011-N-0143, FDA-2011-B-0144, FDA-2011-N-0145, and FDA-2011-N…
Learn More
USP Comments to FDA on Docket No. FDA-2019-N-5464 for Novel Excipient Review Program Proposal; Comments were submitted in 2020.
Learn More
USP comments to FDA on Docket No. FDA-2022-N-0236 for “Prioritizing the Addition of Maximum Daily Exposure Information and Removing Dosage Form Information from the Inactive Ingredient Database.…
Learn More
USP Oral Comments to FDA on Docket No. FDA-2020-N-0025; Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc
Learn More
USP Comments to FDA on draft guidance for Inactive Ingredient Database. Comments were submitted in 2015.
Learn More
USP submitted comments to FDA on Docket No. FDA-2020-N-0025; "Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc" Comments were submitted in 2020.
Learn More
USP Comments to FDA on Docket No. FDA-2019-D-2397; Using the Inactive Ingredient Database; Draft Guidance for Industry. Comments were submitted in 2019.
Learn More
USP comments to FDA for Docket no. FDA-2008-D-0381 Draft Guidance for Industry on Voluntary Third-Party Programs for Food and Feeds. Comments were submitted in 2008.
Learn More
USP Comments to Congress in 2022 regarding the draft of the “Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act” (“PREVENT Pandemics Act”.
Learn More